|  | **Thrombocytopenia Status** | | | **Univariate Regression** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristic** | **Overall**, N = 2651 | **FALSE**, N = 1791 | **TRUE**, N = 861 | **OR**2 | **95% CI**2 | **p-value** |
| **patient\_age\_per\_10** | 5.90 (4.60 - 6.90) | 5.70 (4.05 - 6.70) | 6.25 (5.10 - 7.30) | 1.32 | 1.14, 1.56 | **<0.001** |
| **patient\_age\_60** | 132 (50%) | 81 (45%) | 51 (59%) | 1.76 | 1.05, 2.99 | **0.033** |
| **patient\_age\_65** | 101 (38%) | 62 (35%) | 39 (45%) | 1.57 | 0.93, 2.65 | 0.094 |
| **patient\_sex** | 93 (35%) | 61 (34%) | 32 (37%) | 1.15 | 0.67, 1.95 | 0.6 |
| **patient\_weight\_per\_10** | 5.60 (5.00 - 6.00) | 5.60 (5.00 - 6.00) | 5.55 (5.00 - 6.20) | 1.03 | 0.77, 1.36 | 0.8 |
| **patient\_weight\_50** | 57 (22%) | 36 (20%) | 21 (24%) | 1.28 | 0.69, 2.35 | 0.4 |
| **baseline\_CLCR\_per\_10** | 6.6 (3.0 - 9.9) | 7.2 (4.4 - 10.8) | 4.9 (2.5 - 8.4) | 0.90 | 0.84, 0.96 | **0.001** |
| **baseline\_CLCR\_60** | 120 (45%) | 68 (38%) | 52 (60%) | 2.50 | 1.48, 4.26 | **<0.001** |
| **baseline\_CLCR\_30** | 66 (25%) | 33 (18%) | 33 (38%) | 2.75 | 1.55, 4.92 | **<0.001** |
| **dept\_ER** | 75 (28%) | 46 (26%) | 29 (34%) | 1.47 | 0.84, 2.57 | 0.2 |
| **dept\_ICU** | 110 (42%) | 71 (40%) | 39 (45%) | 1.26 | 0.75, 2.12 | 0.4 |
| **baseline\_HGB\_per\_10** | 10.30 (9.00 - 12.20) | 10.50 (8.95 - 12.35) | 10.00 (9.03 - 11.90) | 0.92 | 0.82, 1.04 | 0.2 |
| **baseline\_WBC\_per\_10** | 1.17 (0.74 - 1.65) | 1.17 (0.72 - 1.60) | 1.18 (0.76 - 1.80) | 1.11 | 0.84, 1.46 | 0.4 |
| **baseline\_PLT\_per\_10** | 21 (13 - 28) | 24 (17 - 30) | 13 (8 - 21) | 0.91 | 0.88, 0.94 | **<0.001** |
| **baseline\_PLT\_200** | 118 (45%) | 59 (33%) | 59 (69%) | 4.44 | 2.58, 7.81 | **<0.001** |
| **baseline\_PLT\_150** | 83 (31%) | 35 (20%) | 48 (56%) | 5.20 | 2.98, 9.21 | **<0.001** |
| **LZD\_duration** | 9.0 (6.0 - 14.0) | 10.0 (6.5 - 14.0) | 9.0 (6.0 - 14.0) | 0.99 | 0.95, 1.03 | 0.8 |
| **LZD\_duration\_7** | 193 (73%) | 134 (75%) | 59 (69%) | 0.73 | 0.42, 1.30 | 0.3 |
| **LZD\_duration\_10** | 131 (49%) | 93 (52%) | 38 (44%) | 0.73 | 0.44, 1.23 | 0.2 |
| **LZD\_duration\_14** | 69 (26%) | 46 (26%) | 23 (27%) | 1.06 | 0.58, 1.88 | 0.9 |
| **invasive\_ETI** | 148 (56%) | 86 (48%) | 62 (72%) | 2.79 | 1.62, 4.93 | **<0.001** |
| **invasive\_CVC** | 135 (51%) | 75 (42%) | 60 (70%) | 3.20 | 1.87, 5.60 | **<0.001** |
| **invasive\_IHD** | 7 (2.6%) | 5 (2.8%) | 2 (2.3%) | 0.83 | 0.12, 3.93 | 0.8 |
| **invasive\_CRRT** | 55 (21%) | 29 (16%) | 26 (30%) | 2.24 | 1.22, 4.12 | **0.009** |
| **comorb\_HTN** | 84 (32%) | 50 (28%) | 34 (40%) | 1.69 | 0.98, 2.90 | 0.059 |
| **comorb\_DM** | 49 (18%) | 31 (17%) | 18 (21%) | 1.26 | 0.65, 2.40 | 0.5 |
| **comorb\_HF** | 19 (7.2%) | 13 (7.3%) | 6 (7.0%) | 0.96 | 0.33, 2.52 | >0.9 |
| **comorb\_angina** | 2 (0.8%) | 2 (1.1%) | 0 (0%) | 0.00 |  | >0.9 |
| **comorb\_cirr** | 14 (5.3%) | 5 (2.8%) | 9 (10%) | 4.07 | 1.36, 13.6 | **0.015** |
| **comorb\_COPD** | 4 (1.5%) | 3 (1.7%) | 1 (1.2%) | 0.69 | 0.03, 5.48 | 0.7 |
| **comorb\_CVA** | 9 (3.4%) | 5 (2.8%) | 4 (4.7%) | 1.70 | 0.41, 6.58 | 0.4 |
| **comorb\_MI** | 2 (0.8%) | 2 (1.1%) | 0 (0%) | 0.00 |  | >0.9 |
| **comorb\_K** | 12 (4.5%) | 8 (4.5%) | 4 (4.7%) | 1.04 | 0.27, 3.41 | >0.9 |
| **infect\_sepsis** | 31 (12%) | 10 (5.6%) | 21 (24%) | 5.46 | 2.50, 12.7 | **<0.001** |
| **infect\_CAP** | 13 (4.9%) | 7 (3.9%) | 6 (7.0%) | 1.84 | 0.58, 5.72 | 0.3 |
| **infect\_HAP** | 139 (52%) | 97 (54%) | 42 (49%) | 0.81 | 0.48, 1.35 | 0.4 |
| **infect\_SSTI** | 18 (6.8%) | 10 (5.6%) | 8 (9.3%) | 1.73 | 0.64, 4.56 | 0.3 |
| **infect\_CNS** | 34 (13%) | 24 (13%) | 10 (12%) | 0.85 | 0.37, 1.82 | 0.7 |
| **infect\_IAI** | 2 (0.8%) | 0 (0%) | 2 (2.3%) | 4,513,741 | 0.00, NA | >0.9 |
| **infect\_UTI** | 12 (4.5%) | 9 (5.0%) | 3 (3.5%) | 0.68 | 0.15, 2.36 | 0.6 |
| **infect\_BJI** | 3 (1.1%) | 3 (1.7%) | 0 (0%) | 0.00 |  | >0.9 |
| **infect\_septicemia** | 98 (37%) | 66 (37%) | 32 (37%) | 1.01 | 0.59, 1.72 | >0.9 |
| **comed\_ibuprofen** | 1 (0.4%) | 0 (0%) | 1 (1.2%) |  |  |  |
| **comed\_carbapenem** | 218 (82%) | 140 (78%) | 78 (91%) | 2.72 | 1.27, 6.52 | **0.016** |
| **comed\_vancomycin** | 23 (8.7%) | 13 (7.3%) | 10 (12%) |  |  |  |
| **comed\_levofloxacin** | 42 (16%) | 30 (17%) | 12 (14%) | 0.81 | 0.38, 1.63 | 0.6 |
| **comed\_teicoplanin** | 9 (3.4%) | 6 (3.4%) | 3 (3.5%) | 1.04 | 0.22, 4.05 | >0.9 |
| **comed\_pyrazinamid** | 13 (4.9%) | 5 (2.8%) | 8 (9.3%) | 3.57 | 1.15, 12.1 | **0.030** |
| **comed\_rifampin** | 14 (5.3%) | 6 (3.4%) | 8 (9.3%) | 2.96 | 1.00, 9.26 | 0.052 |
| **comed\_heparin** | 97 (37%) | 55 (31%) | 42 (49%) | 2.15 | 1.27, 3.66 | **0.004** |
| **comed\_clopidogrel** | 1 (0.4%) | 1 (0.6%) | 0 (0%) |  |  |  |
| **comed\_enoxaparin** | 163 (62%) | 109 (61%) | 54 (63%) | 1.08 | 0.64, 1.85 | 0.8 |
| **comed\_valproic** | 15 (5.7%) | 10 (5.6%) | 5 (5.8%) | 1.04 | 0.32, 3.04 | >0.9 |
| **LZD\_route\_IV** | 265 (100%) | 179 (100%) | 86 (100%) |  |  |  |
| **comed\_aspirin** | 3 (1.1%) | 2 (1.1%) | 1 (1.2%) |  |  |  |
| **comed\_aceclofenac** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_diclofenac** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_naproxen** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_paracetamol** | 144 (54%) | 102 (57%) | 42 (49%) |  |  |  |
| **comed\_penicillin** | 45 (17%) | 31 (17%) | 14 (16%) |  |  |  |
| **comed\_cepha** | 57 (22%) | 41 (23%) | 16 (19%) |  |  |  |
| **comed\_cotrimoxazol** | 32 (12%) | 19 (11%) | 13 (15%) |  |  |  |
| **comed\_daptomycin** | 1 (0.4%) | 1 (0.6%) | 0 (0%) |  |  |  |
| **comed\_ethambutol** | 8 (3.0%) | 4 (2.2%) | 4 (4.7%) |  |  |  |
| **comed\_cetirizin** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_dexamethason** | 96 (36%) | 68 (38%) | 28 (33%) |  |  |  |
| **comed\_amiodaron** | 17 (6.4%) | 6 (3.4%) | 11 (13%) |  |  |  |
| **comed\_furosemid** | 122 (46%) | 65 (36%) | 57 (66%) |  |  |  |
| **comed\_simvas** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_bisoprolol** | 1 (0.4%) | 1 (0.6%) | 0 (0%) |  |  |  |
| **comed\_diltiazem** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_eptifibatid** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_quinidin** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_haloperidol** | 24 (9.1%) | 20 (11%) | 4 (4.7%) |  |  |  |
| **comed\_carbamazepin** | 7 (2.6%) | 7 (3.9%) | 0 (0%) |  |  |  |
| **comed\_phenytoin** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_mirtazapin** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_quetiapin** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_ondansetron** | 3 (1.1%) | 1 (0.6%) | 2 (2.3%) |  |  |  |
| **comed\_palonosetron** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_oseltamivir** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_quinin** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_pembrolizumab** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_trastuzumab** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_atezolizumab** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_durvalumab** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_IVIG** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_tacrolimus** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_fluorouracil** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_irinotecan** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_leucovorin** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **comed\_oxaliplatin** | 0 (0%) | 0 (0%) | 0 (0%) |  |  |  |
| **charlson** | 2.00 (0.00 - 4.00) | 2.00 (0.00 - 3.00) | 3.00 (2.00 - 4.00) | 1.18 | 1.05, 1.33 | **0.007** |
| **baseline\_CLCR** | 66 (30 - 99) | 72 (44 - 108) | 49 (25 - 84) | 0.99 | 0.98, 1.00 | **0.001** |
| **baseline\_CLCR\_factor** |  |  |  |  |  |  |
| 90 <= CLCR < 130 | 46 (17%) | 34 (19%) | 12 (14%) | — | — |  |
| CLCR < 30 | 66 (25%) | 33 (18%) | 33 (38%) | 2.83 | 1.28, 6.59 | **0.012** |
| 30 <= CLCR < 60 | 54 (20%) | 35 (20%) | 19 (22%) | 1.54 | 0.65, 3.72 | 0.3 |
| 60 <= CLCR < 90 | 66 (25%) | 49 (27%) | 17 (20%) | 0.98 | 0.42, 2.36 | >0.9 |
| CLCR >= 130 | 33 (12%) | 28 (16%) | 5 (5.8%) | 0.51 | 0.15, 1.54 | 0.2 |
| **LZD\_dose\_per\_weight** | 21.4 (20.0 - 24.0) | 21.4 (20.0 - 24.0) | 21.6 (19.4 - 24.0) | 1.00 | 0.93, 1.07 | >0.9 |
| **ADR\_onset\_first** | 4.0 (2.0 - 9.0) | NA (NA - NA) | 4.0 (2.0 - 9.0) |  |  |  |
| **ADR\_CTCAE\_max** |  |  |  |  |  |  |
| 1 | 23 (27%) | 0 (NA%) | 23 (27%) |  |  |  |
| 2 | 18 (21%) | 0 (NA%) | 18 (21%) |  |  |  |
| 3 | 23 (27%) | 0 (NA%) | 23 (27%) |  |  |  |
| 4 | 22 (26%) | 0 (NA%) | 22 (26%) |  |  |  |
| **baseline\_PLT** | 209 (129 - 282) | 242 (166 - 300) | 130 (85 - 211) | 0.99 | 0.99, 0.99 | **<0.001** |
| 1Median (IQR); n (%) | | | | | | |
| 2OR = Odds Ratio, CI = Confidence Interval | | | | | | |